Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Alteration of the Mitochondrial Effects of Ceria Nanoparticles by Gold: An Approach for the Mitochondrial Modulation of Cells Based on Nanomedicine

  • Gutiérrez-Carcedo, Patricia
  • Simó, Rafael
  • Setoain, Xavier
  • Aparicio-Gómez, Carolina
  • Abasolo, Ibane
  • Victor, Victor Manuel
  • Herance, José Raúl
  • Navalón Oltra, Sergio|||0000-0001-8423-0759
  • García Gómez, Hermenegildo|||0000-0002-9664-493X
[EN] Ceria nanoparticles are cell compatible antioxidants whose activity can be enhanced by gold deposition and by surface functionalization with positive triphenylphosphonium units to selectively target the mitochondria. The antioxidant properties of these nanoparticles can serve as the basis of a new strategy for the treatment of several disorders exhibiting oxidative stress, such as cancer, diabetes or Alzheimer's disease. However, all of these pathologies require a specific antioxidant according with their mechanism to remove oxidant species excess in cells and diminish their effect on mitochondrial function. The mechanism through which ceria nanoparticles neutralize oxidative stress and their effect on mitochondrial function have not been characterized yet. In the present study, the mitochondria antioxidant effect of ceria and ceria-supported gold nanoparticles, with or without triphenylphosphonium functionalization, was assessed in HeLa cells. The effect caused by ceria nanoparticles on mitochondria function in terms of mitochondrial membrane potential (Delta Psi m), adenosine triphosphate (ATP) production, nuclear respiratory factor 1 (NRF1) and nuclear factor erythroid-2 like 1 (NFE2L1) was reversed by the presence of gold. Furthermore, this effect was enhanced when nanoparticles were functionalized with triphenylphosphonium. Our study illustrates how the mitochondrial antioxidant effect induced by ceria nanoparticles can be modulated by the presence of gold., This research was funded by Carlos III Health Institute and the European Regional Development Fund, grant number CP13/00252 and PI16/1083; the Catalonian Agency for Management of University and Research Grants, grant number 2017SGR1303; the Ministry of Education of the Valencian Regional Government, grant number PROMETEO/2019/027, The Foundation for the Promotion of Health and Biomedical Research of Valencia Region, grant number Nanobetes2.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Phenotyping Type 2 Diabetes in Terms of Myocardial Insulin Resistance and Its Potential Cardiovascular Consequences, A New Strategy Based on 18 F-FDG PET/CT

  • Herance, José Raul|||0000-0001-7178-3290
  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Velasquez, Mayra Alejandra
  • Paun, Bruno
  • García Leon, Daniel|||0000-0001-7199-3079
  • Aparicio-Gómez, Carolina|||0000-0002-0845-2365
  • Marés, Roso|||0000-0002-7339-0172
  • Simó-Servat, Olga|||0000-0003-3483-652X
  • Castell-Conesa, Joan|||0000-0002-6449-9731
  • Hernández, Cristina|||0000-0002-3109-1721
  • Aguadé-Bruix, Santiago|||0000-0001-8617-6274
Background: Systemic insulin resistance is generally postulated as an independent risk factor of cardiovascular events in type 2 diabetes (T2D). However, the role of myocardial insulin resistance (mIR) remains to be clarified. Methods: Two 18 F-FDG PET/CT scans were performed on forty-three T2D patients at baseline and after hyperinsulinemic-euglycemic clamp (HEC). Myocardial insulin sensitivity (mIS) was determined by measuring the increment in myocardial 18 F-FDG uptake after HEC. Coronary artery calcium scoring (CACs) and myocardial radiodensity (mRD) were assessed by CT. Results: After HEC, seventeen patients exhibited a strikingly enhancement of myocardial 18 F-FDG uptake and twenty-six a marginal increase, thus revealing mIS and mIR, respectively. Patients with mIR showed higher mRD (HU: 38.95 [33.81-44.06] vs. 30.82 [21.48-38.02]; p = 0.03) and CACs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Footprint of Type 1 Diabetes on Red Blood Cells, A Metabolomic and Lipidomic Study

  • Herance, José Raul|||0000-0001-7178-3290
  • Ciudin, Andreea|||0000-0001-5622-0203
  • Lamas-Domingo, Rubén
  • Aparicio-Gómez, Carolina|||0000-0002-0845-2365
  • Hernández, Cristina|||0000-0002-3109-1721
  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Palomino-Schätzlein, Martina
The prevalence of diabetes type 1 (T1D) in the world populations is continuously growing. Although treatment methods are improving, the diagnostic is still symptom-based and sometimes far after onset of the disease. In this context, the aim of the study was the search of new biomarkers of the disease in red blood cells (RBCs), until now unexplored. The metabolomic and the lipidomic profile of RBCs from T1D patients and matched healthy controls was determined by NMR spectroscopy, and different multivariate discrimination models were built to select the metabolites and lipids that change most significantly. Relevant metabolites were further confirmed by univariate statistical analysis. Robust separation in the metabolomic and lipidomic profiles of RBCs from patients and controls was confirmed by orthogonal projection on latent structure discriminant analysis (OPLS-DA), random forest analysis, and significance analysis of metabolites (SAM). The main changes were detected in the levels of amino acids, organic acids, creatine and phosphocreatine, lipid change length, and choline derivatives, demonstrating changes in glycolysis, BCAA metabolism, and phospholipid metabolism. Our study proves that robust differences exist in the metabolic and lipidomic profile of RBCs from T1D patients, in comparison with matched healthy individuals. Some changes were similar to alterations found already in RBCs of T2D patients, but others seemed to be specific for type 1 diabetes. Thus, many of the metabolic differences found could be biomarker candidates for an earlier diagnosis or monitoring of patients with T1D.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Identification of Myocardial Insulin Resistance by Using Liver Tests, A Simple Approach for Clinical Practice

  • Herance, José Raul|||0000-0001-7178-3290
  • Martín-Saladich, Queralt|||0000-0003-4798-1558
  • Velásquez, Mayra Alejandra
  • Hernández, Cristina|||0000-0002-3109-1721
  • Aparicio-Gómez, Carolina|||0000-0002-0845-2365
  • Ramírez Serra, Clara|||0000-0001-8971-1711
  • Ferrer Costa, Roser|||0000-0002-8925-3172
  • Giralt-Arnaiz, Marina
  • González Ballester, Miguel Ángel|||0000-0002-9227-6826
  • Pericàs, Juan M.|||0000-0002-3645-3293
  • Castell-Conesa, Joan|||0000-0002-6449-9731
  • Aguadé-Bruix, Santiago|||0000-0001-8617-6274
  • Simó Canonge, Rafael|||0000-0003-0475-3096
Background: We report that myocardial insulin resistance (mIR) occurs in around 60% of patients with type 2 diabetes (T2D) and was associated with higher cardiovascular risk in comparison with patients with insulin-sensitive myocardium (mIS). These two phenotypes (mIR vs. mIS) can only be assessed using time-consuming and expensive methods. The aim of the present study is to search a simple and reliable surrogate to identify both phenotypes. Methods: Forty-seven patients with T2D underwent myocardial [18F]FDG PET/CT at baseline and after a hyperinsulinemic-euglycemic clamp (HEC) to determine mIR were prospectively recruited. Biochemical assessments were performed before and after the HEC. Baseline hepatic steatosis index and index of hepatic fibrosis (FIB-4) were calculated. Furthermore, liver stiffness measurement was performed using transient elastography. Results: The best model to predict the presence of mIR was the combination of transaminases, protein levels, FIB-4 score and HOMA (AUC = 0.95; sensibility: 0.81; specificity: 0.95). We observed significantly higher levels of fibrosis in patients with mIR than in those with mIS (p = 0.034). In addition, we found that patients with mIR presented a reduced glucose uptake by the liver in comparison with patients with mIS. Conclusions: The combination of HOMA, protein, transaminases and FIB-4 is a simple and reliable tool for identifying mIR in patients with T2D. This information will be useful to improve the stratification of cardiovascular risk in T2D.